DR. ALICE NELSON HERLIHY MD
Prescription History 1902013196
Internal Medicine - Pulmonary Disease in North Chesterfield, VA


Quality Rating: 76.5 out of 100 score

NPI Status: Active since May 17, 2007

Contact Information

1000 BOULDERS PKWY
SUITE 200
NORTH CHESTERFIELD, VA
ZIP 23225
Phone: (804) 320-4243
Fax: (804) 622-0552

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ALICE NELSON HERLIHY MD, an active Pulmonary Disease specialist practicing in North Chesterfield, VA. Our medical registry currently tracks 46 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 3,886 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 597 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 58
30-Day Fills 88.0
Days Supply 2,640
VA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills28.4
Peer Average Days Supply831
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 190.0% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,793.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$686.10

State Avg Cost Per Claim

$588.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 44
30-Day Fills 51.0
Days Supply 1,530
VA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills29.4
Peer Average Days Supply879
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 91.3% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,374.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$508.50

State Avg Cost Per Claim

$612.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 513
30-Day Fills 668.5
Days Supply 17,774
VA State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills69.8
Peer Average Days Supply1,712
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 800.0% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,643.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.24

State Avg Cost Per Claim

$46.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Amoxicillin

Generic Formulation: AmoxicillinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 112
VA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.2
Peer Average Days Supply240
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.5% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $57.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.60

State Avg Cost Per Claim

$4.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.

Therapeutic Applications

Amoxicillin is used to treat a wide variety of bacterial infections. This medication is a penicillin-type antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. Amoxicillin is also used with other medications to treat stomach/intestinal ulcers caused by the bacteria H. pylori and to prevent the ulcers from returning.

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 31
30-Day Fills 33.0
Days Supply 338
VA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.8
Peer Average Days Supply227
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 29.2% more claims than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $193.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.23

State Avg Cost Per Claim

$13.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 102
30-Day Fills 144.0
Days Supply 4,320
VA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills41.0
Peer Average Days Supply1,198
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 218.8% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $71,589.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$701.86

State Avg Cost Per Claim

$587.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 35
30-Day Fills 41.0
Days Supply 1,230
VA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply835
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 66.7% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,887.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$311.06

State Avg Cost Per Claim

$307.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 25.8
Days Supply 750
VA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills48.2
Peer Average Days Supply1,403
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.7% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $438.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.74

State Avg Cost Per Claim

$49.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 169
30-Day Fills 211.5
Days Supply 4,758
VA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills36.5
Peer Average Days Supply309
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 397.1% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,255.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.35

State Avg Cost Per Claim

$10.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 204
30-Day Fills 267.0
Days Supply 8,010
VA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills44.1
Peer Average Days Supply1,295
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 518.2% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $112,222.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$550.11

State Avg Cost Per Claim

$525.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 124
30-Day Fills 144.0
Days Supply 4,320
VA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills44.6
Peer Average Days Supply1,334
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 264.7% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $96,284.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$776.49

State Avg Cost Per Claim

$833.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Budesonide-Formoterol Fumarate

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 38
30-Day Fills 50.0
Days Supply 1,490
VA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills20.6
Peer Average Days Supply612
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 123.5% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,844.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$311.71

State Avg Cost Per Claim

$347.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Bupropion Hcl Sr

Generic Formulation: Bupropion HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 17.0
Days Supply 495
VA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills44.9
Peer Average Days Supply1,329
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $290.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.43

State Avg Cost Per Claim

$31.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bupropion is used to treat depression. It can improve your mood and feelings of well-being. It may work by helping to restore the balance of certain natural chemicals (neurotransmitters) in your brain.

Cefdinir

Generic Formulation: CefdinirSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 145
VA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.9
Peer Average Days Supply221
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $340.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.21

State Avg Cost Per Claim

$20.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin.

Therapeutic Applications

Cefdinir is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Clotrimazole

Generic Formulation: ClotrimazoleSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 232
VA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills21.3
Peer Average Days Supply457
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.8% more claims than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $755.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.07

State Avg Cost Per Claim

$27.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.

Therapeutic Applications

Clotrimazole is used to treat skin infections such as athlete's foot, jock itch, ringworm, and other fungal skin infections (candidiasis). This medication is also used to treat a skin condition known as pityriasis (tinea versicolor), a fungal infection that causes a lightening or darkening of the skin of the neck, chest, arms, or legs. Clotrimazole is an azole antifungal that works by preventing the growth of fungus.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 21.0
Days Supply 580
VA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills23.4
Peer Average Days Supply678
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,362.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$609.58

State Avg Cost Per Claim

$645.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 49
30-Day Fills 49.0
Days Supply 393
VA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills31.6
Peer Average Days Supply434
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 69.0% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $603.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.33

State Avg Cost Per Claim

$22.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dulera

Generic Formulation: Mometasone/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 37
30-Day Fills 63.0
Days Supply 1,890
VA State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills19.7
Peer Average Days Supply578
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 146.7% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,965.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$593.65

State Avg Cost Per Claim

$426.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of mometasone furoate and formoterol fumarate that is used as an inhaled dosage form for the treatment of ASTHMA.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: mometasone and formoterol. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Dupixent Pen

Generic Formulation: DupilumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
VA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.7
Peer Average Days Supply564
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $47,580.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,965.06

State Avg Cost Per Claim

$3,716.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dupixent Syringe

Generic Formulation: DupilumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 868
VA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.2
Peer Average Days Supply537
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 72.2% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $122,413.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,948.81

State Avg Cost Per Claim

$3,769.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Eliquis

Generic Formulation: ApixabanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 51
30-Day Fills 55.0
Days Supply 1,650
VA State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills118.3
Peer Average Days Supply3,347
Conservative Utilization

This provider writes prescriptions for this formulation 30.1% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,404.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$655.00

State Avg Cost Per Claim

$843.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Esbriet

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
VA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.1
Peer Average Days Supply630
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $62,259.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,188.30

State Avg Cost Per Claim

$10,715.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Famotidine

Generic Formulation: FamotidineSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 40.0
Days Supply 1,200
VA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.1
Peer Average Days Supply168
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $323.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.11

State Avg Cost Per Claim

$11.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Therapeutic Applications

Famotidine is used to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed. This medication is also used to treat certain stomach and throat (esophagus) problems (such as erosive esophagitis, gastroesophageal reflux disease-GERD, Zollinger-Ellison syndrome). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as cough that doesn't go away, stomach pain, heartburn, and difficulty swallowing. Famotidine belongs to a class of drugs known as H2 blockers. This medication is also available without a prescription. It is used to prevent and treat heartburn and other symptoms caused by too much acid in the stomach (acid indigestion). If you are taking this medication for self-treatment, it is important to read the manufacturer's package instructions carefully so you know when to consult your doctor or pharmacist.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 55
30-Day Fills 95.0
Days Supply 2,850
VA State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills81.3
Peer Average Days Supply2,431
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $841.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.30

State Avg Cost Per Claim

$17.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 39
30-Day Fills 57.0
Days Supply 1,710
VA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills35.4
Peer Average Days Supply1,061
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 50.0% more claims than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,824.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$277.56

State Avg Cost Per Claim

$223.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Furosemide

Generic Formulation: FurosemideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 26.0
Days Supply 733
VA State Average Benchmarks
Peer Average Claims77.0
Peer Average 30-Day Fills155.0
Peer Average Days Supply4,508
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 84.4% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $35.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.93

State Avg Cost Per Claim

$6.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.

Therapeutic Applications

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 43
30-Day Fills 54.0
Days Supply 1,620
VA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills31.2
Peer Average Days Supply869
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 79.2% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,831.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$484.45

State Avg Cost Per Claim

$452.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Levofloxacin

Generic Formulation: LevofloxacinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 190
VA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.7
Peer Average Days Supply199
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $154.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.74

State Avg Cost Per Claim

$9.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The L-isomer of Ofloxacin.

Therapeutic Applications

This medication is used to treat a variety of bacterial infections. Levofloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. Levofloxacin injection is used if you cannot take the medication by mouth. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Methotrexate

Generic Formulation: Methotrexate SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.3
Days Supply 382
VA State Average Benchmarks
Peer Average Claims83.0
Peer Average 30-Day Fills166.6
Peer Average Days Supply4,901
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 84.3% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $243.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.73

State Avg Cost Per Claim

$39.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

Therapeutic Applications

Methotrexate is used to treat certain types of cancer (such as acute lymphoblastic leukemia, non-Hodgkin's lymphoma) or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. It may also be used to control juvenile rheumatoid arthritis. Methotrexate belongs to a class of drugs known as antimetabolites. It works by slowing or stopping the growth of cancer cells and suppressing the immune system. Early treatment of rheumatoid arthritis with more aggressive therapy such as methotrexate helps to reduce further joint damage and to preserve joint function.

Methylprednisolone

Generic Formulation: MethylprednisoloneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 126
VA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills34.5
Peer Average Days Supply230
Conservative Utilization

This provider writes prescriptions for this formulation 38.2% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $203.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.67

State Avg Cost Per Claim

$9.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PREDNISOLONE derivative with similar anti-inflammatory action.

Therapeutic Applications

Methylprednisolone is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases, and immune system disorders. It decreases your immune system's response to various diseases to reduce symptoms such as swelling, pain, and allergic-type reactions. This medication is a corticosteroid hormone. Methylprednisolone may also be used with other medications in hormone disorders.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 337
30-Day Fills 689.7
Days Supply 20,690
VA State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills139.3
Peer Average Days Supply4,157
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 461.7% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,553.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.51

State Avg Cost Per Claim

$19.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Nystatin

Generic Formulation: NystatinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 87
VA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.5
Peer Average Days Supply462
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $170.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.22

State Avg Cost Per Claim

$22.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.

Therapeutic Applications

Nystatin is used to treat fungal skin infections. Nystatin is an antifungal that works by stopping the growth of fungus.

Pantoprazole Sodium

Generic Formulation: Pantoprazole SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 38.0
Days Supply 1,140
VA State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills144.3
Peer Average Days Supply4,282
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.2% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $406.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.46

State Avg Cost Per Claim

$16.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.

Therapeutic Applications

Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pantoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 243
30-Day Fills 274.0
Days Supply 4,268
VA State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills56.5
Peer Average Days Supply1,001
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 417.0% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,069.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.40

State Avg Cost Per Claim

$6.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Proair Respiclick

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 30
30-Day Fills 32.0
Days Supply 758
VA State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills15.2
Peer Average Days Supply386
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 114.3% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,588.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$86.30

State Avg Cost Per Claim

$77.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Roflumilast

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 25
30-Day Fills 41.0
Days Supply 1,190
VA State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills17.7
Peer Average Days Supply528
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 92.3% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,235.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$249.41

State Avg Cost Per Claim

$331.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Handihaler

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 35
30-Day Fills 62.0
Days Supply 1,860
VA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills34.5
Peer Average Days Supply987
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 52.2% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,511.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$957.48

State Avg Cost Per Claim

$747.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 229
30-Day Fills 287.0
Days Supply 8,610
VA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills45.1
Peer Average Days Supply1,346
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 638.7% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $154,540.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$674.85

State Avg Cost Per Claim

$712.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 104
30-Day Fills 166.0
Days Supply 4,980
VA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills47.4
Peer Average Days Supply1,420
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 215.2% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $80,356.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$772.66

State Avg Cost Per Claim

$658.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 251
30-Day Fills 329.0
Days Supply 9,870
VA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills47.4
Peer Average Days Supply1,418
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 684.4% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $132,043.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$526.07

State Avg Cost Per Claim

$568.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 597
30-Day Fills 737.0
Days Supply 22,110
VA State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills73.6
Peer Average Days Supply2,191
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 985.5% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $500,653.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$838.62

State Avg Cost Per Claim

$864.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Varenicline Tartrate

Generic Formulation: Varenicline TartrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 25
30-Day Fills 32.8
Days Supply 956
VA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills20.6
Peer Average Days Supply574
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.3% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,894.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$435.78

State Avg Cost Per Claim

$452.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.

Therapeutic Applications

Varenicline is used by adults to help stop smoking. To increase your chance of success, use this medication with a stop-smoking program that includes education, support, and counseling. Quitting smoking lowers your risk of heart and lung disease, as well as cancer. Varenicline works by blocking nicotine's effects in the brain that make you want to smoke. Discuss the risks and benefits of this medication, as well as other ways to quit smoking (such as nicotine replacement treatment), with your doctor.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 38
30-Day Fills 49.5
Days Supply 1,203
VA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills26.1
Peer Average Days Supply632
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 72.7% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,431.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$90.30

State Avg Cost Per Claim

$78.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 58
30-Day Fills 94.0
Days Supply 2,820
VA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills32.8
Peer Average Days Supply984
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 176.2% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,245.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$418.03

State Avg Cost Per Claim

$271.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 15.0
Days Supply 396
VA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills64.4
Peer Average Days Supply1,847
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.4% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,754.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$704.98

State Avg Cost Per Claim

$925.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Xolair

Generic Formulation: OmalizumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 868
VA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.5
Peer Average Days Supply541
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 63.2% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $83,916.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,706.98

State Avg Cost Per Claim

$3,247.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.

Therapeutic Applications

Omalizumab is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma that is due to year-round allergens. Controlling symptoms of asthma helps you maintain your normal activities and cuts down on time lost from work or school. Omalizumab may also be used to treat nasal polyps or to treat hives from an unknown cause (chronic idiopathic urticaria-CIU). This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, salbutamol) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ALICE NELSON HERLIHY MD provides transparency into local medical care patterns within North Chesterfield, VA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.